Form 4: ResMed Inc. Executive Michael J. Rider Reports Stock Sale
SEC Form 4 Filing
Michael J. Rider, Global General Counsel of ResMed Inc., reports selling 200 shares of ResMed Common Stock on March 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On March 4, 2024, Michael J. Rider, the Global General Counsel of ResMed Inc., filed a Form 4 with the SEC.
- The form reports a transaction that occurred on March 1, 2024, where Rider sold 200 shares of ResMed Common Stock.
- The sale price was $173.25 per share.
- Following the transaction, Rider directly owns 6,688 shares of ResMed Common Stock.
- The transaction was executed under a Rule 10b5-1 plan adopted on November 29, 2023.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding a stock sale by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to use Rule 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- The stock sale by a high-ranking executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2023-11-29 | Date of adoption of the Rule 10b5-1 plan. |
| 2024-03-01 | Date of the stock sale transaction. |
| 2024-03-04 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.